263 related articles for article (PubMed ID: 6584087)
21. [Diagnostic usefulness of serum levels of pancreatic oncofetal antigen (POA) and CA 19-9 in pancreatic cancers: monitoring of postoperative recurrences].
Takami H; Hishinuma S; Shintoku J; Ogata Y; Abe O
Gan No Rinsho; 1985 May; 31(6 Suppl):631-7. PubMed ID: 3861883
[TBL] [Abstract][Full Text] [Related]
22. [Tag 72: a new tumor-associated antigen identified by a monoclonal antibody].
Piantino P; Fusaro A; Daziano E; Polloni R; Mosso R; Cacace G
Minerva Med; 1990 Nov; 81(11):765-7. PubMed ID: 2255410
[TBL] [Abstract][Full Text] [Related]
23. [Basic and clinical studies on the measurement of serum CA 19-9].
Imazeki K; Kitakata Y; Uno K; Koga T; Kawana M; Arimizu N; Saisho H; Uematsu S
Kaku Igaku; 1986 Jun; 23(6):855-61. PubMed ID: 3463815
[No Abstract] [Full Text] [Related]
24. [CA-50: evaluation of a new tumor marker in the diagnosis of neoplastic pathologies of the gastrointestinal tract].
Pecchio F; Ricci E; Rapellino M; Oliaro A; Adamo MR; Marzola G; Piantino P
Minerva Med; 1987 Feb; 78(3):141-4. PubMed ID: 3469541
[TBL] [Abstract][Full Text] [Related]
25. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl Tn antigen: (1). Evaluation of assay conditions and normal values. STN Study Group].
Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3213-9. PubMed ID: 2782915
[TBL] [Abstract][Full Text] [Related]
26. [Basic and clinical studies on ELSA CA 125 RIA kit: usefulness in patients with ovarian carcinoma].
Sakahara H; Endo K; Nakajima K; Nakashima T; Koizumi M; Ohta H; Torizuka K; Konishi I; Fujii S; Mori T
Kaku Igaku; 1985 Sep; 22(9):1391-7. PubMed ID: 3866873
[No Abstract] [Full Text] [Related]
27. [Basic studies and the reference values of cancer associated antigen CA-50].
Yoshioka H; Shitara M; Sakurabayashi I; Kawai T; Suzuki M
Rinsho Byori; 1988 Feb; 36(2):171-6. PubMed ID: 3288785
[No Abstract] [Full Text] [Related]
28. [Basic and clinical evaluation of measurement of pancreatic cancer associated antigen, SPan-1].
Chung YS; Nakata B; Tanaka H; Kubo T; Satake K; Sowa M; Umeyama K
Nihon Geka Gakkai Zasshi; 1990 Feb; 91(2):228-33. PubMed ID: 2325607
[TBL] [Abstract][Full Text] [Related]
29. [CA 19-9 in early cancers of the bronchi. Comparison with the carcinoembryogenic antigen].
Vindimian M; Lafitte JJ; Wattre P
Biomed Pharmacother; 1987; 41(4):191-5. PubMed ID: 3476162
[TBL] [Abstract][Full Text] [Related]
30. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
31. [Detection of DU-PAN-2 antigen (pancreatic cancer-associated antigen) in sera of patients with cancer of the digestive tract].
Takami H; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3207-14. PubMed ID: 3777958
[TBL] [Abstract][Full Text] [Related]
32. [Monoclonal antibodies in the radioimmunological diagnosis of malignant tumors of the gastrointestinal tract and ovaries].
Tkacheva GA; Blokhina NG; Klimenkov AA; Kozachenko VP
Vopr Onkol; 1985; 31(5):36-42. PubMed ID: 2409674
[TBL] [Abstract][Full Text] [Related]
33. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve.
Kim HJ; Kim MH; Myung SJ; Lim BC; Park ET; Yoo KS; Seo DW; Lee SK; Min YI
Am J Gastroenterol; 1999 Jul; 94(7):1941-6. PubMed ID: 10406263
[TBL] [Abstract][Full Text] [Related]
34. [A study of the clinical usefulness of the CA15-3 radioimmunoassay kit].
Abe Y; Odagiri E; Jibiki K; Demura R; Demura H
Gan No Rinsho; 1988 Oct; 34(12):1672-6. PubMed ID: 3193612
[TBL] [Abstract][Full Text] [Related]
35. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for 2----6 sialyl Lewis a antigen--2. Evaluation of clinical significance].
Imura H; Takahashi T; Matsuda T; Yoshida O; Ohkura H; Seitetsu Y; Seino Y; Ishii M; Kuwabara M; Ariyoshi Y
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2203-12. PubMed ID: 2660749
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of a serum pancreatic tumor marker: the carbohydrate antigen C.A. 19-9].
Vincent D; Venot J; Catanzano G; Clément MN; Piquet MF; Veyriras E; Beck C
Ann Med Interne (Paris); 1985; 136(2):142-4. PubMed ID: 3865571
[TBL] [Abstract][Full Text] [Related]
37. Comparison of four 'second generation' immunoassay systems to determine CA 125 in serum by using a graphical approach to method comparison analysis.
Koper NP; Thomas CM; Massuger LF; Segers MF; Kiemeney LA; Verbeek AL
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):617-23. PubMed ID: 9298352
[TBL] [Abstract][Full Text] [Related]
38. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of tumor-associated antigen of the digestive tract by monoclonal antibody].
Imai K; Hinoda Y; Yachi A
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2185-90. PubMed ID: 3606145
[TBL] [Abstract][Full Text] [Related]
40. [Basic and clinical studies on SPan-1 RIABEAD kit: usefulness in patients with pancreatic and biliary tract cancer].
Watanabe Y; Endo K; Nakajima K; Hattori N; Sakahara H; Saga T; Nakai T; Hosono M; Yao ZS; Baba N
Kaku Igaku; 1989 Dec; 26(12):1559-65. PubMed ID: 2622087
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
